

## Special Issue

# ESKAPE and MDRO Pathogens: Infections and Antimicrobial Treatment

### Message from the Guest Editor

ESKAPE and MDRO pathogens are still a growing concern, with an estimated enormous mortality in next decades. New antibiotics are going to be available and others are progressing in the pipeline. The appropriate use of these antibiotics should be a cornerstone of our daily activities in order to preserve them and to reduce the clinical and economical impact of antibiotic resistance. Several questions are still open in the field of antibiotic treatment: role of combination therapy, treatment duration, antibiotics administration, and place in therapy of BLIC and new antibiotics, among many others. This Special Issue will contribute to answering these and other arising questions about the treatment of ESKAPE and other MDRO infections.

---

### Guest Editor

Dr. Carlo Pallotto

Infectious Diseases Clinic, Department of Medicine, Santa Maria della Misericordia Hospital, University of Perugia, 06132 Perugia, Italy

---

### Deadline for manuscript submissions

closed (31 October 2025)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.2  
Indexed in PubMed



[mdpi.com/si/218224](https://mdpi.com/si/218224)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.2  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)